According to the report, the global cardiac biomarker diagnostic kits market was valued at US$ 2.2 Bn in 2021 and is anticipated to grow at a CAGR of 5.2% from 2022 to 2030
Wilmington, Delaware, United States, Transparency Market Research Inc. – According to Transparency Market Research’s latest report on the Global Cardiac Biomarker Diagnostic Kits market for the historical period 2017–2018 and forecast period 2019–2027, rising prevalence of cardiovascular disorders across the globe and advancements in novel technologies are projected to drive the global cardiac biomarker diagnostic kits market during the forecast period
According to the report, the global cardiac biomarker diagnostic kits market was valued at US$ 2.2 Bn in 2021 and is anticipated to grow at a CAGR of 5.2% from 2022 to 2030
Rising prevalence of cardiovascular diseases across the globe : Key Driver
Growing prevalence of cardiovascular disorders across the globe is a key factor driving the global cardiac biomarker diagnostic kits market.
Download Sample @ https://qyresearchmedical.com/sample/111612
For instance, as per World Health Organization (WHO), every year around 17.9 million people die due to cardiovascular diseases globally which constitutes an estimated 31% of all deaths worldwide.
Advancements and technological innovations prompt patients to opt for easy-to-use and portable medical devices, which is also fuelling the growth of global cardiac biomarker diagnostic kits market
Moreover, rising government funding for cardiovascular disease treatment, early detection to track the heart condition, and integration of cardiology & IT are also some of the major factors responsible for the growth of global cardiac biomarker diagnostic kits market
Lack of trained staff and appropriate health care infrastructure in developing economies hamper the market growth
A cardiac biomarker involves various technical skills, which require appropriate training to handle the device. Sometimes, hospitals or people from developing countries lack awareness about the biomarker and its handling. It creates a barrier between the manufacturing of the device and usage, thereby restraining the market
Also Lack of awareness in developing countries and Negative impact of economic constraint in certain regions & pricing pressure can restrain the global market growth
Global Cardiac Biomarker Diagnostic Kits Market: North America dominated the global market
On the basis of region, the cardiac biomarker diagnostic kits market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
North America region is accounted for major market share in the global market owing to higher patient population for cardiac diseases, expansion of high-sensitive cardiac biomarkers, rise in acceptance of point-of-care instruments by hospitals and clinics, advancements in technology, and development of high sensitivity POC testing in the region
However, Asia-Pacific region is considered as the most lucrative market during the forecast period from 2019 to 2027. The growth is mainly attributed to developing health care infrastructure, large patient population, increase in funding and investment toward the development of cardiac analyzers, and surge in focus of both international and domestic players in the region
Global Cardiac Biomarker Diagnostic Kits Market: Competitive Landscape
This report profiles major players in the global cardiac biomarker diagnostic kits market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global cardiac biomarker diagnostic kits market is highly consolidated, with a few global players accounting for a major share in market.
Leading players operating in the global Cardiac biomarker diagnostic kits market are
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Siemens Healthineers
- bioMérieux SA
- Ortho Clinical Diagnostics
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- among others
Global Cardiac Biomarker Diagnostic Kits Market: Key Developments
Key players in the global cardiac biomarker diagnostic kits market are engaged in regulatory approvals, new product development, technological advancements, merger, acquisitions & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cardiac biomarker diagnostic kits market. A few expansion strategies adopted by players operating in the global Cardiac biomarker diagnostic kits market are:
In April 2019, US FDA has approved Ortho Clinical Diagnostics VITROS XT MicroSlides which features new, multi-test technology that allows labs to run two tests simultaneously on one MicroSlide
In September 2018, Abbott receives CE Mark for first troponin test to help predict the chance of heart attack in apparently healthy adults potentially months to years in advance.
The report on the global cardiac biomarker diagnostic kits market discussed individual strategies, followed by company profiles of manufacturers of cardiac biomarker diagnostic kits. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cardiac biomarker diagnostic kits market
Key Questions Answered in Global Cardiac biomarker diagnostic kits market Report
- What is the scope of growth of product companies in the global cardiac biomarker diagnostic kits market?
- What will be the Y-o-Y growth of the global cardiac biomarker diagnostic kits market between 2019 and 2027?
- What is the influence of changing trends in changing technologies on the global cardiac biomarker diagnostic kits market?
- Will North America continue to be the most profitable market for cardiac biomarker diagnostic kits providers?
- Which factors are anticipated to hamper the growth of the global cardiac biomarker diagnostic kits market during the forecast period?
- Which are the leading companies in the global cardiac biomarker diagnostic kits market?
Global Cardiac biomarker diagnostic kits market – Segmentation
Product
- Troponin Test Kits
- CK-MB Test Kits
- Myoglobin Test Kits
- BNP Test Kits
- C-reactive Protein (hsCRP)
- Other Biomarkers
Application
- Angina Pectoris
- Myocardial Infarction (MI)
- Cardiac Heart Failure
- Others
Testing
- Laboratory Testing
- Point-of-care Testing
End-user
- Hospitals
- Clinics
- Diagnostic Laboratory
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111612/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/
